Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

[1]  R. Pazdur,et al.  First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer , 2014, Clinical Cancer Research.

[2]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[3]  Richard Pazdur,et al.  Pathological complete response and accelerated drug approval in early breast cancer. , 2012, The New England journal of medicine.

[4]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  ชัยยุทธ เจริญธรรม.  Primary systemic therapy of breast cancer , 2011 .

[6]  R. Paridaens,et al.  Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Wanders,et al.  Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. , 2010, Clinical breast cancer.

[8]  Leslie Wilson,et al.  Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. , 2010, Biochemistry.

[9]  A. Buzdar,et al.  A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. , 2010, Clinical breast cancer.

[10]  David A. Smith,et al.  Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Wong,et al.  Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors Cancer Therapy: Clinical , 2022 .

[12]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Barbara L. Smith,et al.  Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Terry L. Smith,et al.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Jordan,et al.  The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth , 2005, Molecular Cancer Therapeutics.

[16]  J. Doroshow,et al.  A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial , 2005 .

[17]  T. Julian,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Wickerham,et al.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[20]  Melvin J. Yu,et al.  In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. , 2001, Cancer research.

[21]  D. Sargent,et al.  A three-outcome design for phase II clinical trials. , 2001, Controlled clinical trials.

[22]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[23]  T. Julian,et al.  Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study , 2014, Breast Cancer Research and Treatment.